Meeting
2021 Genitourinary Cancers Symposium
Phase I with expansion clinical trial of seleno-l-methionine (SLM) in combination with axitinib in patients with relapsed clear cell renal cell carcinoma (ccRCC): Bench to bedside.
Authors
Yousef Zakharia
University of Iowa, Iowa City, IA
Yousef Zakharia , Ryan Reis , Rohan Garje , Umang Swami , Janelle M Born , James A. Brown , Kenneth Gerard Nepple , Bashar Abuqayas , Maheen Rajput , Andrew Bellizzi , Jessica C Sieren , Youcef M. Rustum
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02535533
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 322)
DOI
10.1200/JCO.2021.39.6_suppl.322
Abstract #
322
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
Preliminary results of phase I clinical trial of high doses of seleno-L-methionine (SLM) in sequential combination with axitinib in previously treated and relapsed clear cell renal cell carcinoma (ccRCC) patients.
First Author: Rohan Garje
Poster
2015 Genitourinary Cancers Symposium
DART Study: A phase II randomized trial of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma (RCC): Results from Part 1.
First Author: Martin Henner Voss
Poster
2012 ASCO Annual Meeting
Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with renal cell carcinoma (RCC) from a phase I study.
First Author: Igor Puzanov
Poster
2024 ASCO Genitourinary Cancers Symposium
A phase II study of neoadjuvant tislelizumab and axitinib in patients with locally advanced non-metastatic clear cell renal cell carcinoma (accRCC).
First Author: Shun Zhang